SOURCE: Streetwise Reports

Streetwise Reports

February 22, 2016 09:00 ET

Van Leeuwenhoeck's Marcel Wijma Interviewed by The Life Sciences Report

SAN FRANCISCO, CA --(Marketwired - February 22, 2016) - Stock analysts fall into a few different categories. There are buyside analysts and sellside analysts, and then there are independent analysts commissioned by companies to highlight underexposed business models and growth prospects. The independent analyst, such as Van Leeuwenhoeck's Marcel Wijma, normally works in the small- and micro-cap stock universe, where the buyside and sellside rarely go. In this interview with The Life Sciences Report, Wijma brings to light five diverse, overlooked small-cap biotech stocks from Canada, Europe and Australia that could bring huge returns to investor portfolios.

Included in this interview are: Regeneus Ltd. (ASX: RGS), Resverlogix Corp. (TSX: RVX) and OncoSil Medical Ltd. (ASX: OSL).

The Life Sciences Report : You have written about the inherent problems with investment bank research. You imply that it is difficult for sellside analysts to perform unbiased diligence on stocks. Is there a place for sellside research, or should investors avoid it?

Marcel Wijma: Actually, there will always be a place for sellside analysts. Investors should not avoid sellside research. However, in some sectors, like biotechnology, it's getting more challenging because most investment banks, especially the larger ones, are focusing on large-cap companies. They don't do any reports on the smaller companies. The reason is very simple: They earn less money with the smaller companies' initial public offerings or secondary placements of equity or debt. It boils down to how much income can be derived. That's why I think there is definitely a place for independent research, which focuses more on micro- and small-cap companies. Small companies are...

Continue reading this interview: Circling the Globe for Uncommon Biotech Opportunities: Van Leeuwenhoeck's Marcel Wijma

About Streetwise Reports -- The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that help you capitalize on developing trends.

DISCLOSURE:

Regeneus Ltd. and Resverlogix Corp. are sponsors of Streetwise Reports. OncoSil Medical Ltd. paid to distribute. Marcel Wijma had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Mr. Wijma and not of The Life Sciences Report or its officers. The interview does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.

Please see Streetwise Reports' terms of use and full legal disclaimer.

Contact Information